File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adiponectin as a therapeutic target for obesity-related metabolic and cardiovascular disorders

TitleAdiponectin as a therapeutic target for obesity-related metabolic and cardiovascular disorders
Authors
KeywordsAdipokine
Adiponectin
Cardiovascular disease
Diabetes
Obesity
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/34597
Citation
Drug Development Research, 2006, v. 67 n. 8, p. 677-686 How to Cite?
AbstractObesity is the major risk factor for the metabolic syndrome, which encompasses a cluster of inter-related metabolic risk factors for type 2 diabetes mellitus (T2DM), atherosclerosis, and cardiovascular diseases. Adiponectin, a major adipokine secreted from adipocytes, plays an important role in obesity-related metabolic and cardiovascular diseases. Longitudinal studies from different ethnic groups have identified low levels of plasma adiponectin (hypoadiponectinemia) to be an independent risk factor for T2DM, hypertension, and coronary artery diseases. On the other hand, results from various animal models have demonstrated the role of adiponectin as an insulin-sensitizer with potent anti-diabetic, anti-atherogenic, anti-inflammatory, and cardio-protective activities. Therefore, upregulation of endogenous adiponectin production by pharmacological and/or dietary interventions might have multiple beneficial effects on obesity-related disorders. A number of pharmacological agents that increase adiponectin production have recently been identified. Among them, the anti-diabetic actions of the PPARγ agonists, thiazolidinediones (TZDs), are mediated, at least in part, by induction of adiponectin expression. Here, we summarize the recent progress on clinical and pharmacological studies of adiponectin, and discuss the utility of adiponectin as a target to develop novel therapies for treatment and prevention of obesity-related metabolic and cardiovascular diseases. © 2006 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/163051
ISSN
2015 Impact Factor: 0.984
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWang, Yen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorXu, Aen_HK
dc.date.accessioned2012-09-05T05:26:59Z-
dc.date.available2012-09-05T05:26:59Z-
dc.date.issued2006en_HK
dc.identifier.citationDrug Development Research, 2006, v. 67 n. 8, p. 677-686en_HK
dc.identifier.issn0272-4391en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163051-
dc.description.abstractObesity is the major risk factor for the metabolic syndrome, which encompasses a cluster of inter-related metabolic risk factors for type 2 diabetes mellitus (T2DM), atherosclerosis, and cardiovascular diseases. Adiponectin, a major adipokine secreted from adipocytes, plays an important role in obesity-related metabolic and cardiovascular diseases. Longitudinal studies from different ethnic groups have identified low levels of plasma adiponectin (hypoadiponectinemia) to be an independent risk factor for T2DM, hypertension, and coronary artery diseases. On the other hand, results from various animal models have demonstrated the role of adiponectin as an insulin-sensitizer with potent anti-diabetic, anti-atherogenic, anti-inflammatory, and cardio-protective activities. Therefore, upregulation of endogenous adiponectin production by pharmacological and/or dietary interventions might have multiple beneficial effects on obesity-related disorders. A number of pharmacological agents that increase adiponectin production have recently been identified. Among them, the anti-diabetic actions of the PPARγ agonists, thiazolidinediones (TZDs), are mediated, at least in part, by induction of adiponectin expression. Here, we summarize the recent progress on clinical and pharmacological studies of adiponectin, and discuss the utility of adiponectin as a target to develop novel therapies for treatment and prevention of obesity-related metabolic and cardiovascular diseases. © 2006 Wiley-Liss, Inc.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/34597en_HK
dc.relation.ispartofDrug Development Researchen_HK
dc.rightsDrug Development Research. Copyright © John Wiley & Sons, Inc.-
dc.subjectAdipokineen_HK
dc.subjectAdiponectinen_HK
dc.subjectCardiovascular diseaseen_HK
dc.subjectDiabetesen_HK
dc.subjectObesityen_HK
dc.titleAdiponectin as a therapeutic target for obesity-related metabolic and cardiovascular disordersen_HK
dc.typeArticleen_HK
dc.identifier.emailWang, Y: yuwanghk@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/ddr.20141en_HK
dc.identifier.scopuseid_2-s2.0-33845277369en_HK
dc.identifier.hkuros129069-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33845277369&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume67en_HK
dc.identifier.issue8en_HK
dc.identifier.spage677en_HK
dc.identifier.epage686en_HK
dc.identifier.isiWOS:000242272700005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWang, Y=34973733700en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats